Acadian Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Acadian Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625K	Sell	62,657 -117,353	-65%	-$1.06M	﹤0.01%	1384
2026 Q1	$1.71M	Buy	180,010 +94,710	+111%	+$736K	﹤0.01%	1006
2025 Q4	$662K	Sell	85,300 -754,103	-90%	-$5.45M	﹤0.01%	1226
2025 Q3	$6.36M	Buy	839,403 +467,631	+126%	+$3.89M	0.01%	575
2025 Q2	$3.33M	Sell	371,772 -298,589	-45%	-$2.78M	0.01%	690
2025 Q1	$5.02M	Buy	670,361 +475,564	+244%	+$3.84M	0.01%	497
2024 Q4	$1.46M	Buy	194,797 +183,472	+1,620%	+$1.39M	﹤0.01%	846
2024 Q3	$85K	Buy	+11,325	New	+$86.1K	﹤0.01%	1644
2020 Q3	–	Sell	-15,932	Closed	-$76K	–	2170
2020 Q2	$76K	Sell	15,932 -175,832	-92%	-$702K	﹤0.01%	1790
2020 Q1	$383K	Buy	+191,764	New	+$528K	﹤0.01%	1031

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Acadian Asset Management's BCRX Position: Q2 2026 in Review

Acadian Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 65% in Q2 2026, selling an estimated $1.06M and leaving 62,657 shares worth $625K. The position accounts for ﹤0.01% of the portfolio, ranked #1384.

Acadian Asset Management first reported a position in BCRX in Q1 2020 and has held it in 10 quarters since. The position peaked at $6.36M in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Acadian Asset Management held 62,657 shares of BioCryst Pharmaceuticals worth $625K as of Q2 2026.
Acadian Asset Management sold 117,353 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
BioCryst Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1384 holding.
Acadian Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
Acadian Asset Management's BioCryst Pharmaceuticals position peaked at $6.36M in Q3 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.